Statements (44)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:approves |
many countries
|
| gptkbp:brand |
gptkb:Zestril
gptkb:Vasotec gptkb:Lotensin gptkb:Quinapril gptkb:Altace Ramipril Accupril Fosinopril Monopril Perindopril |
| gptkbp:class |
angiotensin-converting enzyme inhibitors
|
| gptkbp:commonName |
5-40 mg daily
|
| gptkbp:contraindication |
pregnancy
angioedema renal artery stenosis |
| gptkbp:developedBy |
pharmaceutical companies
|
| gptkbp:examples |
Enalapril
Lisinopril Ramipril |
| gptkbp:formulation |
tablet
liquid |
| https://www.w3.org/2000/01/rdf-schema#label |
ACEI
|
| gptkbp:interactsWith |
NSAIDs
lithium diuretics |
| gptkbp:is_monitored_by |
renal function
potassium levels |
| gptkbp:issuedBy |
oral tablet
|
| gptkbp:lastProduced |
1981
|
| gptkbp:marketedAs |
various brand names
|
| gptkbp:partOf |
cardiovascular therapy
|
| gptkbp:provides |
first-line treatment for hypertension
recommended for heart failure |
| gptkbp:researchFocus |
chronic kidney disease
diabetes management cardiovascular outcomes |
| gptkbp:sideEffect |
cough
low blood pressure hyperkalemia |
| gptkbp:triggerType |
inhibiting angiotensin-converting enzyme
|
| gptkbp:usedFor |
hypertension
heart failure |